Roche Receives EMA CHMP Recommendation Of Approval Ocrevus For Pediatric Patients With Relapsing Forms Of Multiple Sclerosis

Roche has received a positive recommendation from the EMA's CHMP for its drug Ocrevus, aimed at pediatric patients with relapsing forms of multiple sclerosis (MS). This follows the U.S. FDA's approval in May 2026, and a final decision from the European Commission is anticipated soon. The recommendation is based on the Phase III OPERETTA 2 study, which demonstrated that Ocrevus reduced the risk of relapses by 48% compared to the current standard treatment, fingolimod, while also showing significant reductions in brain inflammation. Approximately 40,000 children and adolescents are affected by MS globally, highlighting the importance of this treatment option.